- Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical announces positive topline results from a Phase 3 clinical trial, ATLAS, evaluating a once-per-month injectable two-drug regimen for the maintenance treatment of HIV-1 infection.
- The study demonstrated the non-inferiority of Janssen's long-acting rilpivirine plus ViiV Healthcare's cabotegravir compared to a daily oral three-drug regimen at week 48.
- Complete results will be submitted for presentation at a future medical conference.
J&J's long-acting injectable two-drug regimen successful in late-stage HIV study
Recommended For You
About JNJ Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
JNJ | - | - |
Johnson & Johnson |